[HTML][HTML] Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase …
R Bissonnette, DM Pariser, NR Wasel… - Journal of the American …, 2016 - Elsevier
Background Difficult-to-treat palmoplantar psoriasis has a disproportionately negative
impact on quality of life. Objective We evaluated the efficacy and safety of apremilast in …
impact on quality of life. Objective We evaluated the efficacy and safety of apremilast in …
[PDF][PDF] Robert M. Day, PhD, d Rongdean Chen, PhD, d and Michael Sebastian, MD e Montreal, Quebec, and Edmonton, Alberta, Canada; Norfolk, Virginia; Summit …
R Bissonnette, DM Pariser, NR Wasel, J Goncalves - cytokines, 2016 - core.ac.uk
Background: Difficult-to-treat palmoplantar psoriasis has a disproportionately negative
impact on quality of life. Objective: We evaluated the efficacy and safety of apremilast in …
impact on quality of life. Objective: We evaluated the efficacy and safety of apremilast in …
[HTML][HTML] Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase …
R Bissonnette, DM Pariser, NR Wasel… - Journal of the American …, 2016 - jaad.org
Background Difficult-to-treat palmoplantar psoriasis has a disproportionately negative
impact on quality of life. Objective We evaluated the efficacy and safety of apremilast in …
impact on quality of life. Objective We evaluated the efficacy and safety of apremilast in …
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III …
R Bissonnette, DM Pariser, NR Wasel… - Journal of the …, 2016 - europepmc.org
Methods A post hoc analysis of data pooled from phase IIb (PSOR-005) and phase III
(Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1 and 2) …
(Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1 and 2) …
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III …
R Bissonnette, DM Pariser, NR Wasel… - Journal of the American …, 2016 - infona.pl
Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality
of life. We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis. A post …
of life. We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis. A post …
[PDF][PDF] Robert M. Day, PhD, d Rongdean Chen, PhD, d and Michael Sebastian, MD e Montreal, Quebec, and Edmonton, Alberta, Canada; Norfolk, Virginia; Summit …
R Bissonnette, DM Pariser, NR Wasel, J Goncalves - cytokines, 2016 - researchgate.net
Background: Difficult-to-treat palmoplantar psoriasis has a disproportionately negative
impact on quality of life. Objective: We evaluated the efficacy and safety of apremilast in …
impact on quality of life. Objective: We evaluated the efficacy and safety of apremilast in …
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III …
R Bissonnette, DM Pariser, NR Wasel… - Journal of the …, 2016 - hero.epa.gov
BACKGROUND: Difficult-to-treat palmoplantar psoriasis has a disproportionately negative
impact on quality of life. OBJECTIVE: We evaluated the efficacy and safety of apremilast in …
impact on quality of life. OBJECTIVE: We evaluated the efficacy and safety of apremilast in …
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III …
R Bissonnette, DM Pariser… - Journal of the …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Difficult-to-treat palmoplantar psoriasis has a disproportionately negative
impact on quality of life. Objective We evaluated the efficacy and safety of apremilast in …
impact on quality of life. Objective We evaluated the efficacy and safety of apremilast in …